−0.050 SGD
−939.92 K SGD
8.65 M SGD
About PHARMESIS INTL
Sector
CEO
Xue Dan Wu
Headquarters
Singapore
Website
Founded
1996
ISIN
SG1BH6000003
FIGI
BBG000CP0KW0
Pharmesis International Ltd. is an investment holding company, which engages in the research, development, production, sale, and marketing of medicine and medicine formulated products for the treatment of illnesses relating to the liver and gall bladder. It operates through the following segments: Western Drugs, Traditional Chinese Medicine Formulated Drugs, and Distribution. The Western Drugs segment involves in the chemically formulated drugs and is marketed under the Kinna brand. The Traditional Chinese Medicine Formulated Drugs segment offers traditional Chinese medicine and is marketed under the Longlife brand. The Distribution segment includes agency products and internally manufactured products which are marketed through the distribution arm. The company was founded in 1996 and is headquartered in Singapore.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of BFK is 0.575 SGD — it has increased by 4.50% in the past 24 hours. Watch PHARMESIS INTL stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on SGX exchange PHARMESIS INTL stocks are traded under the ticker BFK.
BFK stock has fallen by −0.85% compared to the previous week, the month change is a −6.45% fall, over the last year PHARMESIS INTL has showed a 486.73% increase.
BFK stock is 4.35% volatile and has beta coefficient of 1.24. Track PHARMESIS INTL stock price on the chart and check out the list of the most volatile stocks — is PHARMESIS INTL there?
Today PHARMESIS INTL has the market capitalization of 17.59 M, it has decreased by −7.50% over the last week.
Yes, you can track PHARMESIS INTL financials in yearly and quarterly reports right on TradingView.
BFK net income for the last half-year is −650.05 K SGD, while the previous report showed −730.37 K SGD of net income which accounts for 11.00% change. Track more PHARMESIS INTL financial stats to get the full picture.
No, BFK doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. PHARMESIS INTL EBITDA is −589.10 K SGD, and current EBITDA margin is −2.09%. See more stats in PHARMESIS INTL financial statements.
Like other stocks, BFK shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade PHARMESIS INTL stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So PHARMESIS INTL technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating PHARMESIS INTL stock shows the buy signal. See more of PHARMESIS INTL technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.